Abzu vs Modulari-T

<p>Abzu is a biotechnology software platform that leverages artificial intelligence to develop advanced RNA therapies such as siRNAs, ASOs, and anti-miRs for major medical needs. It integrates deep RNA biology knowledge with AI-driven design and drug development expertise, enabling you to explore and prioritize vast RNA sequence variants computationally. This reduces experimental costs, shortens candidate selection time, and improves overall drug design efficiency.</p> <p>The platform also supports targeted RNA delivery by developing programmable aptamers for cell-specific uptake, creating a modular system for precision beyond traditional liver-focused delivery. Abzu serves biotech researchers and pharmaceutical teams aiming to innovate RNA drug development, offering case studies and AI models that enhance therapeutic design safety and efficacy. While currently fundraising, Abzu emphasizes explainable AI to boost pharma trust and streamline workflows.</p>

<p>Modulari-T provides cutting-edge biotechnology software solutions centered on Modular Actuation Receptor Cells (MARC), which are synthetic immune receptors designed for high efficacy and safety across diverse cell types. It enables you to leverage these receptors to improve immune cell therapies by preventing early T cell exhaustion and enhancing their persistence, making cell therapies more functional and long-lasting.</p> <p>With Modulari-T, you also gain access to the Modular Vector (MoVE) platform for in vivo delivery of these engineered receptors, targeting immune cells like T cells and NK cells. This combination offers scalable, off-the-shelf cell therapy options that are backed by peer-reviewed science, making it a promising tool for researchers and healthcare professionals working on cancer immunotherapy and advanced cell therapy development.</p>